Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | PPARG | P37231 | 3/20 | 0.58 |
| ▸ | PPARA | Q07869 | 1/20 | 0.58 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PPID | Q08752 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173008 | 0.91 | PPARG (0.53) | LMNAMAPTSMN1; SMN2PPARGPPARA | |
| SCHEMBL15538944 | 0.87 | SMN1; SMN2 (0.59) | LMNAMAPTSMN1; SMN2PPARGPPARA | |
| SCHEMBL12872176 | 0.87 | PPARG (0.54) | LMNAMAPTSMN1; SMN2PPARGPPARA | |
| SCHEMBL7972075 | 0.86 | CYP4F2 (0.56) | LMNAMAPTSMN1; SMN2PPARGPPARA | |
| SCHEMBL3004723 | 0.85 | MAPT (0.53) | LMNAMAPTSMN1; SMN2PPARGPPARA | |
| SCHEMBL3004728 | 0.85 | MAPT (0.53) | LMNAMAPTSMN1; SMN2PPARGPPARA | |
| SCHEMBL29142984 | 0.84 | L3MBTL1 (0.59) | MAPTSMN1; SMN2PPARGPPARACYP17A1 | |
| SCHEMBL28306385 | 0.84 | PPARG (0.49) | LMNAMAPTSMN1; SMN2PPARGPPARA | |
| SCHEMBL6371460 | 0.84 | LMNA (0.48) | LMNAMAPTSMN1; SMN2PPARGPPARA | |
| SCHEMBL8786889 | 0.83 | MAPT (0.51) | LMNAMAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109879805-B | Preparation method of apatinib | 苏州富士莱医药股份有限公司 | 2020-08-07 | — | — | CN | disclosed |
| EP-3456719-A1 | COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3456719-A1 | COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| CN-108727307-A | Compound and its application method | 安吉奥斯医药品有限公司 | 2018-11-02 | — | — | CN | disclosed |
| US-10087172-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| CN-104936954-B | Compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2018-08-14 | — | — | CN | disclosed |
| EP-2922850-B1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2922850-B1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-15 | — | — | US | disclosed |
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-15 | — | — | US | disclosed |
| EP-2922850-A1 | COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| CN-104936954-A | compounds and methods of use thereof | AGIOS PHARMACEUTICALS INC | 2015-09-23 | — | — | CN | disclosed |
| US-9029531-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029531-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2014079136-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014079150-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014079136-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142081-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142081-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291576-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | LMNA 3690/4885MAPT 3239/4885SMN1; SMN2 3742/4885 |
| US-10087172-B2 | Compounds and their methods of use | GLS, GLS2, GLUL | LMNA 3690/4885MAPT 3239/4885SMN1; SMN2 3742/4885 |
| US-20140142081-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | LMNA 3478/4885MAPT 3597/4885SMN1; SMN2 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.